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ABSTRACT

Calabro, Mark Nicholas. M.S., Microbiology and Immunology Graduate Program, Wright State
University, 2021. Investigating Streptococcus pneumoniae and Adenovirus Co-Infections of Lung
Epithelial Cells

Co-infection is common among viruses and bacteria in the human respiratory system.
Adenovirus (AdV) and Streptococcus pneumoniae are clinically relevant respiratory pathogens
that cause morbidity and mortality in a variety of patient populations with the highest
morbidity occurring among immunocompromised individuals, but also prevalent in infants and
the elderly. Acute respiratory distress syndrome may become severe in healthy individuals
when co-infection with S. pneumoniae and AdV occurs due to synergistic effects of the
pathogens on the host. I hypothesized that S. pneumoniae infection decreases AdV
transduction of airway epithelia. To test this hypothesis, we utilized the polarized immortalized
airway epithelial cell line Calu-3. Calu-3 cells were inoculated with S. pneumoniae followed by
the addition of recombinant adenovirus, AdVLacZ. Then, the effect of bacteria on AdV
transduction into Calu-3 cells was determined by quantifying β-galactosidase. Cell-associated
viral genomes were measured by quantitative polymerase chain reaction. These results showed
that S. pneumoniae infection decreased significantly AdV transduction in Calu-3 cells, but there
was no significant difference in quantity of cell-associated AdV genomes.
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I.

INTRODUCTION AND BACKGROUND

Adenovirus
Adenovirus (AdV) is a non-enveloped icosahedral virus that contains double stranded
DNA (12). There are 50 strains of adenovirus. (28) AdV can invade and infect several cell types
in humans, and infections can lead to many clinical illnesses. Human AdV is highly
communicable and usually causes mild symptomatic illness but can also lead to severe and even
fatal infections (1). AdV is commonly responsible for upper and lower respiratory tract
infections, gastrointestinal (GI) tract infections, and conjunctivitis (2, 3). These infections are
more likely to be seen epidemically in children (lacking humoral immunity), closed communities
(military recruits), and those with impaired immune systems (e.g., patients with Human
immunodeficiency virus 1 infection, organ transplant recipients) (6). Immunocompromised
patients are highly susceptible to viral disease, leading to significant morbidity and mortality.
This project focuses on respiratory illness caused by adenovirus.
Adenovirus as a Gene Therapy Vector
Because of their high transmissibility, recombinant adenovirus vectors have become
popular and often investigated for gene therapy. However, the toxicity and immune response to
AdV-mediated gene therapy has become a daunting obstacle to overcome (10, 11).
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Adenovirus Vector Vaccines
Pharmaceutical companies have developed adenovirus vector vaccines to combat the
COVID-19 pandemic. They include the Johnson & Johnson (Jannsen), AstraZeneca, Gamaleya,
and CanSino Biologics vaccines (34).
Transmission
Transmission of adenovirus occurs by close personal contact and by respiratory droplets
in the air spread by coughing and sneezing. Touching an object or surface with adenoviruses on
it, then touching your mouth, nose, or eyes before washing your hands can also spread the virus.
Pathogenesis of Respiratory Infection
Human adenovirus causes common cold or flu-like symptoms, fever, sore throat, acute
bronchitis, and pneumonia.
Risk Factors
People with decreased immune function are more susceptible to human adenovirus.
Diagnosis
The main diagnostic test for human adenovirus is real-time polymerase chain reaction
(PCR) assay.
Prevention
Vaccination against adenovirus is currently only given to military recruits. The military
adenovirus vaccination program was re-instated March 2011. Barr Labs Inc. manufactures the
vaccine, which is given as one dose of two oral tablets containing live Adenovirus Type 4 and
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Type 7 (29). Implementation of good health practices like hand hygiene, cough etiquette, and
staying home when sick can also help control the transmission of adenovirus.
Streptococcus pneumoniae
Streptococcus pneumoniae is a gram-positive alpha-hemolytic commensal organism (4,
13). The pneumococcal polysaccharide capsule has more than 90 distinct serotypes. S.
pneumonia can cause infection in the middle ear, sinus infection, pneumonia, bacteremia, and
meningitis. Pneumonia with empyema, bacteremia, and meningitis are invasive infections (30).
Pneumococcal bacteria are the most common cause of pneumonia. Young children and the
elderly are most susceptible to infection (5).
Virulence factors
S. pneumoniae has several virulence factors that help it evade the immune system. The
capsular polysaccharide inhibits opsonization by blocking fixation of complement leading to
activation of the alternative pathway of complement. Pneumococcal surface protein C (PspC)
recruits Factor H to the pathogen membrane to inactivate bound C3b. This prevents formation of
the membrane attack complex (MAC) (33). The capsule also blocks detection of two cell wall
components, peptidoglycan, and lipopolysaccharide (LPS), by pattern recognition receptors
(PRRs) found on macrophages, neutrophils, and dendritic cells. These receptors recognize
microbial-associated molecular pattern (MAMPs), also referred to as pathogen-associated
molecular patterns (PAMPs) that are part of the pathogen (33). The capsule also serves as a
platform for antigenic variation. Over 90 serotypes of S. pneumoniae are known. Infection with
one serotype can lead to type-specific immunity. This protects from reinfection with that specific
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serotype, but not with a different serotype. Thus, each serotype of S. pneumoniae presents as a
distinct pathogen to the adaptive immune system (33).

Symptoms
Pneumonia:
Symptom onset typically appears 1-3 days after exposure. Fever, chills,
productive cough, dyspnea, tachypnea or tachycardia, hypoxia, and
malaise.
Meningitis:
Stiff neck, fever, headache, photophobia (eyes being more sensitive to
light), and confusion.
Bacteremia:
Confusion or disorientation; Shortness of breath; High heart rate; Fever.
shivering, or feeling very cold; Extreme pain or discomfort; Clammy
or sweaty skin (30).
Transmission
Transmission of S. pneumoniae occurs through direct person-to-person contact with
respiratory secretions like saliva or mucus (27). Certain percentages of the population carry S.
pneumoniae as commensal flora of the oral pharynx.
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Risk Factors
Pediatric populations with increased risk factors for contracting pneumococcal disease
include children under the age of 2, who have certain illnesses (sickle cell disease, HIV infection,
diabetes, immune compromising conditions, nephrotic syndrome, or chronic heart, lung, kidney,
or liver disease). Children with cochlear implants or cerebrospinal fluid (CSF) leaks (escape of
the fluid that surrounds the brain and spinal cord (27).
Adults over the age of 65 are at increased risk of contracting pneumococcal disease.
Some adults 19 through 64 years old are also at increased risk for pneumococcal disease,
including those with chronic illnesses (chronic heart, liver, kidney, or lung disease; diabetes; or
alcoholism). Immunocompromised patients (HIV/AIDS, cancer, or damaged/absent spleen) carry
a higher risk of disease as do patients with cochlear implants or cerebrospinal fluid (CSF) leaks
and adults who smoke cigarettes (27).
Prevention
The Center for Disease Control and Prevention’s Advisory Committee on Immunization
Practices (ACIP) recommends routine vaccination of infants with a 4-dose series of PCV13
(Pneumococcal Conjugate Vaccine 13 capsular subtypes) and of adults aged 65 years or older
with 1 dose of PPSV23 (Pneumococcal Polysaccharide Vaccine 23 capsular subtypes) (26).
Table 1 shows an overview of approved pneumococcal vaccines in the United States.
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Trade
Name

Abbreviation Manufacturer

Doses
In
routine
Series

Approved
Ages

Comments

Pneumovax
23
Prevnar 13

PPSV23

Merck

1

≥ 2 years

Inactivated polysaccharide

PCV13

Pfizer

4

≥ 6 weeks

Inactivated, Adj. CRM197
conjugate

Table 1 Approved Pneumococcal Vaccines in the United States (29)
Good health practices like hand hygiene, cough etiquette, and staying home when sick
can also help control the transmission of S. pneumoniae.
Diagnosis
Definitive diagnosis of S. pneumoniae typically relies on culture isolation of the bacteria
from sterile body sites. For example, blood cultures from a patient with invasive pneumonia (30).
Culture confirmation of pneumonia should include antibiotic susceptibility reporting. A urinary
antigen test for the C-polysaccharide antigen of S. pneumoniae is available to test for community
acquired pneumonia in adult patients. Abbott’s BINAXNOW Streptococcus pneumoniae
Antigen Card can test for the detection of S. pneumoniae in urine as well as the cerebral spinal
fluid (CSF) of patients with meningitis (32).
Treatment
Mild respiratory illness can be self-resolving with over-the-counter drugs for
symptomatic management for outpatient populations. Treatment guidelines set forth by the
Infectious Disease Society of America are complex, considering patient age, immune status, comorbidities, setting, and prognosis (30). Empiric treatment of ear infections and pneumonia in
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children consists of penicillin and cephalosporins. Data show that pneumococcal bacteria are
resistant to one or more antibiotics in 30% of cases (30).
Adenovirus Entry into Host Cells
Adenovirus enters the host cell through the Coxsackievirus and Adenovirus Receptor
(CAR) or more specifically, the eight-exon encoded alternatively spliced isoform, CAR Ex8. The
receptor may fulfill a critical role in adenovirus/Streptococcus pneumoniae co-infection. CAR
receptors are involved in cell-cell adhesion, protein trafficking, and viral infection (24). CAREx8
has previously been shown to be located on the apical surface of epithelial airway cells where it
is able to mediate AdV infection from the apical surface (22). Moreover, the CAR Ex8 isoform is
up-regulated by the pro-inflammatory cytokine IL-8 and smoke (23). S. pneumoniae can infect
the same airway epithelial cells as adenovirus. A more thorough look at CAR could give insight
into the effect of adenovirus/Streptococcus pneumoniae co-infection.
Bacterial/Viral Co-Infections
Bacterial-viral co-infections are common, especially in children under five and in
immunocompromised individuals (6, 15-17,19). While one study showed that co-infections with
AdV and S. pneumoniae are one of the most prevalent compared to other AdV and bacteria coinfections (1), another study has suggested that the combined number of cases reported is modest
(15-17). It is possible the combined number of cases may be under reported because viral and
bacterial respiratory infections are common, and they can display similar symptoms (sore
throat/postnasal drip, bronchitis/cough, congestion/running nose, earaches, and development of
pneumonia) (14, 21). The detection of one does not necessarily indicate the absence of the other
(5, 18). Normally, the human immune system can eliminate minor bacterial and viral respiratory
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infections, but a single infection may change an individual’s immunity and pathology (5, 19),
which could leave an individual more susceptible to subsequent infection. Despite the occurrence
of co-infection, not much is understood about the effects of viral/bacteria co-infections and what
their synergistic effects may be. While it has been shown that AdV plays a role in the adherence
of S. pneumoniae to the airway epithelial cells, how S. pneumonia affects AdV infection is
completely unknown (8). Understanding the effect of one pathogen on another may result in
better understanding of how the body deals with co-infections, as well as novel therapeutic
approaches for treating these infections.
A model is required to examine the effects Streptococcus pneumoniae/Adenovirus coinfection on lung epithelia. This thesis explores a model system to investigate co-infection by the
addition of Streptococcus pneumoniae followed by recombinant human adenovirus.
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II. MATERIALS AND METHODS

Bacterial Culture
Bacterial cultures were manipulated in a certified biological safety cabinet using aseptic
technique and Biosafety Level 2 conditions. Bacterial culture and co-infection experiments were
carried out in the Microbiology Laboratory at Wright State University.
Initiation of Bacterial Growth:
Streptococcus pneumoniae strain (ATCC49619) was ordered from American Type
Culture Collection (ATCC; Manassas, VA). Bacterial culture was initiated using the protocol
supplied by ATCC. Briefly, 0.5 mL of Todd Hewitt Broth (Item No. 249240; BD Biosciences)
with 0.02% Yeast Extract (Item No. 11929; BD Biosciences) was added to the freeze-dried
culture shipment and mixed. The entire suspension was transferred to a sterile Pyrex screw cap
culture tube (100 mm X 13 mm, 9 mL Fisher 14-933A) containing 5 to 6 ml of Todd Hewitt
Broth with 0.02% Yeast Extract (THY). Additionally, several drops of the suspension were
transferred to a 5% blood agar plate, for streaking and pure culture solation. Cultures were
incubated at 37°C with an atmosphere of 5% CO2 for 24 hours. Additional test tubes were
inoculated by transferring 0.5 mL of the primary culture to additional secondary culture tubes.
The blood agar plate cultures were observed for expected colonial morphology of S.
pneumoniae.
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Preparation of Streptococcus pneumoniae Bacterial Stocks:
The initial bacterial cultures described above were subcultured onto new 5% blood agar
plates, streaking for isolation, and new 9 ml screw cap culture tubes containing 8 ml THY broth.
The blood agar plates were incubated overnight 16-18 hours in a candle jar at 37°C. The broth
culture tubes were capped tightly and incubated at 37°C and grown to mid-log growth phase,
defined as 0.2- 0.6 OD at 600 nm. Optical density was measured by Thermo Scientific Genesys
20 Spectrophotometer using the tube reader insert for the instrument. The broth cultures of S.
pneumoniae were then aliquoted into 2 ml cryogenic tubes (Nalgene, Thermo Scientific)
containing 20% Glycerol (Amresco). The vials were frozen at -80°C in an ultra-low freezer.
Bacterial Growth for Co-infection
Streptococcus pneumoniae strain (ATCC49619) was grown on BD Trypticase Soy Agar
II with 5% sheep blood agar plates from Beckton Dickinson (Item No. B21261X; Fisher
Scientific) overnight ~16-18 hours in a candle jar at 37°C. The morning of the co-infection
experiment, the jar was opened, and 8-10 individual colonies were transferred using a sterile loop
into a 9 ml screw cap culture tube containing 8 ml of THY Broth. Three culture tubes were
inoculated this way. Tubes were capped tight, mixed gently, and incubated at 37 °C to mid-log
growth phase (determined as 0.2- 0.6 OD at 600 nm measured by Thermo Scientific Genesys 20
Spectrophotometer using the tube reader insert for the instrument. In early experiments, the
bacteria were also counted on a hemacytometer before co-infection. A 10 ul sample of the
bacteria was used to charge one side of the hemacytometer. The number of cells occupying four
mini-squares within the central square were counted, averaged, and multiplied by the
hemacytometer coefficient to calculate the concentration of bacteria per milliliter.
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A S. pneumoniae dose-response curve was tried in later experiments. A milliliter of
sample of the mid log-phase culture was spun down in a mini-centrifuge for three minutes. The
supernatant was aspirated with a pipette taking care not to disturb the bacterial pellet. The pellet
was gently resuspended in one ml of phosphate buffered saline (PBS) +/+ (containing Mg+2 and
Ca+2). A dilution series was made as follows: 100 ul of the original bacterial PBS +/+ microtube
was added to a microtube containing 900 ul of PBS +/+ and mixed by inversion and pipetting;
100 ul from this dilution were taken from the dilution of the original sample and mixed in a
microtube with 900 ul PBS +/+. Undiluted cultures are referred to as “High” and first and second
dilutions as “Medium” 10-1 and “Low” 10-2 concentration of S. pneumonia, respectively.
Bacterial Viable Cell Counts:
To check the number of viable Streptococcus pneumonia used in co-infection
experiments, a viable cell count was performed during each experiment. From the tubes used
above for co-infection, an additional dilution series was made in PBS +/+ as follows: 10-1, 10-3,
10-5, and 10-6. Dilutions were mixed by gentle inversion and pipetting. One blood agar plate was
divided into quadrants for each serial dilution concentration from a single sample. Plates were
“spotted” by pipetting 10ul of the dilution using a Ranin AutoRep repeater pipette making 8-10
replicate “spots”.
The spots were allowed to absorb before the plates were incubated in a candle jar at 37°C
overnight (16-18 hours). The number of colonies per 10 ul spot was counted the following
morning and averages calculated for each sample. This average was multiplied by the dilution
factor to calculate the colony forming units per milliliter (CFU/ml). Typically, 10-5 dilution spots
were counted yielding an estimate of 107 CFU/ml Streptococcus pneumoniae for the undiluted
culture.
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Epithelial Cell Culture
To evaluate the hypothesis, the proposed model of experimentation was implemented by
inoculating Calu-3 (ATCC® HTB55™) cells with Streptococcus pneumoniae strain
(ATCC49619) followed by transduction with Ad5CMVCytoLacZ (University of Iowa-3554).
Cell cultures were manipulated in a certified biological safety cabinet using aseptic technique
and good laboratory practice under Biosafety Level 2 conditions.
Growth Medium
Calu-3 (ATCC® HTB55™) cells were grown in 75 cm2 treated tissue culture flasks
with angled necks and vented caps with 10m L of culture media. Culture medium used: RPMI
1640 (Gibco, ThermoFisher Scientific; Item No. 31800089) with 25 mM HEPES (Gibco,
ThermoFisher Scientific; Item No. 15630080) added for extra buffering capacity. PenicillinStreptomycin (10,000 U/ml) (Gibco, ThermoFisher Scientific; Item No. 15140122) was added to
culture medium to help prevent bacterial contamination. Medium was supplemented with 10%
Fetal Bovine Serum (Gibco™, ThermoFisher Scientific; Item No. 26400044). The pH was
adjusted to 7.35 as measured using a Metler Toledo pH meter. The pH Meter’s calibration curve
was run each time before measuring media pH. Culture media was vacuum filter-sterilized using
a 0.22 um Millipore Steritop filter (Fisher Scientific; Item No. S2GVT05RE) in cell culture
hood.
Growth Conditions
Calu-3 cells were incubated at 37°C with an atmosphere of 5% CO2 in a humidified
Sanyo incubator.
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Cell Culture Maintenance
Calu-3 cell media was changed every 2-3 days, culture flasks were observed for
morphology and confluence using an inverted tissue culture microscope (Motic model AE2000).
Passage of Cells
Calu-3 cells were allowed to grow to around 80% confluence in 75cm2 flasks. Typically,
this growth took five days. To passage cells, an aliquot of Trypsin-EDTA (Gibco, ThermoFisher;
Catalog No. 25200056) was warmed in 37° C water bath for five minutes. Calu-3 culture media
was removed using a serologic pipette. Cells were rinsed gently with five ml of PBS -/- (without
Ca+2 or Mg +2). After PBS -/- was added, the flask was gently rocked by hand, and PBS -/- was
aspirated. Two ml of Trypsin EDTA was added into the flask. The flask was incubated at 37°C
with five percent CO2 for 5-10 minutes. After incubation, the flask was gently rocked and
observed under the inverted tissue culture microscope for cell dissociation. Trypsinization was
stopped by adding eight ml of Calu-3 culture media to the flask with a serological pipette. Cells
were gently mixed by pipetting up and down. Calu-3 cells were passed into three new flasks by
adding three ml of the trypsinized cells to seven ml of fresh Calu-3 culture medium. Volumes of
trypsinized cells and fresh media were adjusted to achieve desired cell concentrations.
Seeding Calu-3 cells onto Transwell Plate Inserts
Calu-3 cells were studied using an in vitro experimental model developed in the
laboratory. Using 24-well standard tissue culture treated plates (Corning Falcon, Catalog No.
353226) with a transwell insert PET membrane, 0.4 um pore size (Corning, Catalog No. 3470)
enabled the establishment of an air/liquid interface that resembles how the cells grow in vivo as
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lung epithelial cells. This provided a polarized epithelial layer with an apical air interface and
basolateral liquid culture media interface.
The above-mentioned cell culture maintenance and passaging methods were followed.
Instead of passaging cells to new culture flasks, the trypsinized cells were transferred into a 15
ml conical tube (Falcon) and centrifuged for five minutes at room temperature at a speed of 152
RCF, acceleration 5/10, brake 5/10 in an Eppendorf 5810 R centrifuge. The supernatant was
aspirated in the tissue culture hood and the cells were re-suspended gently in five ml fresh media.
A hemocytometer was used to count the total number of CaLu-3 cells added to each 0.4
µm transparent PET membrane insert to ensure consistent amounts added.
Ten microliters of the cell suspension was used to charge one side of the hemacytometer. Cells in
the four corners of the hemacytometer were counted, averaged, and multiplied by the
hemacytometer coefficient to obtain the concentration of cells per milliliter. The concentration
was adjusted with media to 8.0 x 105 cells/ml. The number of Calu-3 cells used to seed each well
is 2.0 x 105 suspended in 250 µl culture media.
The Calu-3 cell suspension was gently mixed after the concentration was adjusted. Using
a manual Ranin AutoRep repeater pipette, 250 µl of the cell suspension was gently pipetted onto
0.4 µm pore containing transparent PET membranes that was inserted into a multi-well 24 well
tissue culture treated polystyrene plates. After cells were seeded, 500 µl of fresh Calu-3 media
was added to the well (basolateral surface) of the tissue culture plate using Ranin AutoRep
repeater pipette. The plate lid was put on and secured with parafilm. The plate wells were
observed using the tissue culture microscope. Plates were incubated under the conditions
described above.
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After an overnight incubation of about 16-18 hours, the apical media was aspirated.
Taking great care to not disturb the cells bound to the membrane. The plate wells were observed
using the tissue culture microscope. Plates were then placed back into the incubator at 37°C with
five percent CO2 humidified atmosphere. During the incubation, the basolateral media was
replaced every two to three days. Cells were checked microscopically for morphology and
confluence. Growth of a polarized epithelia on the membranes took about 10-12 days before
using the wells for co-infection experiments.
Trans-Epithelial Electrical Resistance (TEER, or TER)
Tight junction formation of the Calu-3 cells was evaluated by measuring Trans-Epithelial
Electrical Resistance (TEER, or TER) using a EVOM2 Voltomhmeter, according to the
manufacturer’s protocol. To check TEER, 250 ul of Calu-3 media was carefully pipetted at an
angle against the side of the transwell insert onto the apical surface of the cells. This was done
using the Ranin AutoRep repeater pipette with a micro-pipette tip attached to the repeater syringe
tip. The basolateral media was aspirated and replaced with 500 ul of fresh Calu-3 media. The
TEER electrode was then submerged into each transwell, the reading was allowed to stabilize
over several seconds, and recorded. After measurement, the apical media was carefully aspirated.
Plates were sealed with parafilm, checked under the inverted microscope, and placed back into
the incubator. The TEER was measured several times during cell growth on the membranes.
Within 24 hours of beginning the co-infection experiment, TEER was measured to ensure that
the cell tight junctions are intact. A threshold TEER reading of 1000 Ohms or greater was used
to establish tight junction integrity. Cell morphology and confluence will be assessed using an
inverted tissue culture microscope from Motic (model AE2000). Polarized epithelia growth took
10-12 days before co-infection experiments.
15

Adenovirus
A recombinant, replication-deficient Adenovirus was purchased from University of Iowa
Carver College of Medicine’s Viral Vector Core- 3554 Ad5CMVCytoLacZ (hereon referred to
as Adenovirus LacZ). The recombinant virus offers episomal gene expression and can infect
dividing and non-diving cells. The viral vector was kept frozen at -80°C in an ultra-low freezer.
All viral vector work was carried out at Biosafety Level 2 conditions using good laboratory
practice inside a biological safety cabinet. The viral solution for co-infection was prepared as
follows: 0.75 ul of concentrated viral stock per transwell was used. The viral stock was diluted
with sterile PBS +/+ to give a volume of 20 ul diluted viral stock per transwell infected. This was
done in a sterile microcentrifuge tube and mixed by pipetting and vortexing. Yielding
multiplicity of infection (MOI) of 125 viral particles per Calu-3 cell.
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Co-infection Procedure
Co-infection experiments were carried out in the biological safety cabinet of the
Microbiology Laboratory at Wright State University.
The 24-well plate enabled testing several conditions between the addition of adenovirus
and S. pneumoniae in replicate. Conditions as described in the table below.

Initial
Infection
for

PBS

Broth

Streptococcus
pneumonia

PBS

Streptococcus
pneumonia

Adenovirus

Adenovirus

Adenovirus

PBS

PBS

4 hours

Followed
by:
For 1 hour

Table 2 Experimental Conditions
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Initial infection was carried out by adding 50 ul of S. pneumoniae or PBS +/+ or THY
broth as controls. The 24-well plate was resealed with parafilm and incubated at 37°C with
humidified air supplemented with five percent CO2 for four hours.
Secondary infection was carried out by adding 20 µl of the diluted Adenovirus stock
solution or PBS +/+ as control. The 24-well plate was resealed with parafilm and incubated at
37°C with humidified air supplemented with five percent CO2 for one hour.
After the secondary infection incubation time was finished, 250 µl of PBS +/+ was gently
pipetted onto the apical surface of the Calu-3 cells and aspirated by pipette. This served as a
wash step. The 24-well plate was finally resealed with parafilm and incubated at 37°C with
humidified air supplemented with five percent CO2 overnight (16-18 hours).
Preparation of Calu-3 Cells for Co-Infection
Within 24 hours of experimentation, the TEER of Calu-3 cells was checked to ensure
tight-junction integrity. In the morning of co-infection experiments, fresh antibiotic-free, serumfree culture media was prepared. Two hundred fifty microliters of PBS +/+ was used to gently
rinse the apical surface of the Calu-3 cells to remove any media. Basolateral media was aspirated
and replaced with antibiotic-free, serum-free media. Plates were sealed with parafilm, checked
using the tissue culture microscope, and transferred to the tissue culture incubator in the
Microbiology Laboratory at Wright State University.
Preparation of Bacteria for Co-Infection
For sample conditions requiring addition of bacteria, 50 µl of the Streptococcus
pneumoniae suspended in THY broth was pipetted onto the apical surface of the Calu-3 cells.
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This was done using a Ranin AutoRep repeater pipette with a sterile syringe tip. Bacteria was
cultured for co-infection as described above.
Preparation of Adenovirus for Co-Infection
For sample conditions requiring Adenovirus, 20 µl of the diluted viral stock was pipetted
onto the apical surface of the Calu-3 cells. Yielding an MOI of 125 viral particles per Calu-3
cell. This was done using a Ranin AutoRep repeater pipette with a sterile syringe tip.
Preparation of PBS+/+ for Co-Infection
For sample conditions requiring PBS+/+ used as a control, 50 µl was used for initial
infection, or 20 µl for the secondary infection.
Beta Galactosidase Assay and Bradford Total Protein Assay
After the co-infection incubation finished, the Calu-3 cells were lysed for total protein
assay followed by a beta galactosidase assay to measure adenovirus transduction.
Sample Lysis
One hundred twenty microliters of Tropix Lysis solution (Applied Biosystems) diluted at
a ratio of 1:5 total volume with deionized H2O was added to the transwell inserts. Using an
Eppendorf Research Plus 200 µl adjustable micropipette the cells were gently scraped from the
PET membrane, mixed, and transferred to a sterile micro-centrifuge tube. To ensure maximum
sample recovery, the transwell insert membranes were cutout using a scalpel and placed into the
same micro-centrifuge tube as the sample lysate. The tubes were vortexed, then centrifuged for
five minutes at room temperature at 17,000 x g in a Thermo Scientific Sorvall Legend Micro 17.
Sample supernatant was transferred to a new micro-centrifuge tube.
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Bradford Assay
BioRad protein assay dye was diluted at a ratio of 1:5 final volume with deionized H2O.
Six microliters of the well-mixed sample lysis from above was pipetted into a plastic one
ml cuvette. Five hundred microliters of the diluted dye added to the plastic cuvette using a Ranin
AutoRep repeater pipette. Sample absorbance was measured at 595 nm on Eppendorf
BioPhotometer plus. 6132. Protein concentration was calculated using the standard curve
established in the lab: y = 0.0474 (ABS) (1000-fold dilution) - 0.0278
Beta galactosidase Assay
β-Galactosidase assay was performed using Applied Biosystems Galacton-Plus™
Substrate and reaction buffer and Light Emission Accelerator-II. Luminescence was read on a
BioTek SynergyTM H1. The luminescence was normalized to the total protein concentration of
the sample to quantify adenovirus transduction of the Calu-3 cells.
A volume of two µl of the above well-mixed sample lysate was pipetted into 96-well flatbottom optically clear microplate. Galacton Plus was diluted at a ratio of 1:100 with the Galacto
Reaction Buffer Diluent. Using a Ranin AutoRep repeater pipette, 100 µl of the diluted Galacton
Plus was pipetted into the sample microplate wells. The plate was then covered with a lid, placed
inside a Styrofoam box, and incubated for 60 minutes at room temperature in the dark. After
incubation, 150 µl of Tropix accelerator II was added to the sample wells and the plate was
immediately read for luminescence using the BioTek SynergyTM H1.
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DNA Isolation and Quantitative PCR Analysis
DNA isolation from Calu-3 on transwell inserts was accomplished by using Qiagen
DNeasy-Blood-Tissue following the manufacturer’s protocol. Samples to quantify the amount of
dsDNA in each of the sample using a Nanodrop One (thermo-fisher). Employing the data from
the Nanodrop, an adjustment can be assessed for each dsDNA sample concentration to ensure
equal loading of template. qPCR was performed using Applied Biosystems QuantStudioTM 7
Flex Real-Time PCR thermocycler (Life Technologies, ThermoFisher) following the
manufacturer’s protocol. QuantaBio PerfeCTa SYBR Green SuperMix Low ROX Catalog
Number: 95096 qPCR master mix was used in 10 ul reaction volume.
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Component
PerfeCTa TA SYBR Green
SuperMix Low ROX (2X)
Forward Primer
Reverse Primer
Template
Table 3 QPCR Mix

Volume for 10 µl Reaction
5.0 µl

Final Concentration
1X

0.5 µl
0.5 µl
4.0 µl

100nM
100nM
48ng

IDT Ready Made Primers for human GAPDH Housekeeping gene control.
Primer

IDT Catalog Number

DNA Sequence (5' to 3')

GAPDH Forward Primer

51-01-07-12

ACC ACA GTC CAT GCC
ATC AC

GAPDH Reverse Primer

51-01-07-13

TCC ACC ACC CTG TTG
CTG TA
ACGCCTCGGAGTACCTG
AG
GTGGGGTTTCTGAACTT
GT

Adenovirus Hexon Forward
Adenovirus Hexon Reverse

Table 4 Primer Sequence

Initial Denaturation and
Activation
QPCR Cycling 40 Cycles
Denaturation
Primer Binding, Elongation,
Data Collection
Melt Curve
Denaturation
Start
Data Collection
End
Table 5 QPCR method

Temperature

Time

95° C

10 Minutes

95° C

10 Seconds

59° C

1 minute

95° C
59° C
0.05° C
95° C

1 minute
30 Seconds
1 second
30 Seconds
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III. RESULTS
The experimental conditions were as follows:
1. A mock bacterial infection of cells with PBS for four hours followed by AdLacZ for one
hour.
2. A mock bacterial infection of cells with sterile Todd Hewitt broth with yeast extract for
four hours followed by AdV for one hour.
3. An initial infection of cells with S. pneumoniae for four hours followed by AdLacZ for
one hour.
4. Negative control (cells not infected with either S. pneumoniae or AdVs)
5. An Initial infection of cells with S. pneumoniae for four hours followed by PBS for one
hour was a positive control for bacterial infection but a negative control for Adv.

Comparing the results can help determine if there is a difference in initial infection of
lung epithelial cells with S. pneumoniae and subsequent infection with adenovirus. The
hypothesis is that there will be a decrease in viral transduction of Calu-3 epithelia during coinfection compared to adenovirus infection alone. Each sample was measured in duplicate to
ensure validity of the results. These cells were treated in wells on four diﬀerent plates where each
plate contained multiple samples for each experimental condition (replicates). Conditions 1, 2,
and 3 are the conditions of interest, so they are the only experimental conditions that were
included in the statistical analysis. There are four response variables of interest: protein
concentration, luminescence, the ratio of these two measures (luminescence: protein
concentration), and cell-associated viral genomes as measured by quantitative PCR (qPCR).
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Protein Concentration
Protein quantitation is often necessary before processing protein samples for further
testing and is often used to normalize measurements since cell numbers can vary from well-towell. Protein quantitation was performed using a Bradford assay as described in Materials and
Methods section. The protein concentration was then used to normalize the luminescence values
of the Beta galactosidase assay. Ideally, no significant differences amongst the conditions would
be present. Denoting equal extraction efficacy. However, there is strong evidence to suggest
there is a signiﬁcant mean diﬀerence between the protein concentrations for condition 2 (Broth,
Adenovirus) and condition 3 (S. pneumoniae, Adenovirus) (p value = 0.0033) (Figure 1). No
other signiﬁcant diﬀerences were detected.
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Figure 1: Boxplot for protein concentration ug/ul by condition. N.S. means no significant
difference between conditions. ** There is strong evidence to suggest there is a signiﬁcant mean
diﬀerence between the protein concentration means for condition 2 and 3 (p value = 0.0033).
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Luminescence
A luminescence assay was used to determine the β-galactosidase protein production from
the LacZ reporter gene encoded in the recombinant adenovirus. β-galactosidase production
indicates viral transduction of the Calu-3 cells. The results of the experiments provide strong
evidence to suggest there is a signiﬁcant mean diﬀerence between the natural log of the
luminescence for conditions 1 and 2 (p value = 0.03) (Figure 2). There is also strong evidence to
suggest there is a signiﬁcant mean difference between the natural log of the luminescence for
condition 1 and 3 (p- <0.0001). Lastly, there is strong evidence to suggest there is a signiﬁcant
mean diﬀerence between the natural log of the luminescence for condition 2 and 3 (p value
<0.0001). There is no difference between conditions 3, 4, and 5.
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Figure 2. Boxplots for luminescence by condition. * Significant difference between condition 1
and 2, (p value = 0.03). *** Significant difference in the conditions of interest (3) compared to
condition 1 and 2, where both p values were <0.0001.
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Ratio of Luminescence/Protein Concentration
The ratio is determined by using the results of the luminescence assay and dividing by
protein concentration. This allows the luminescence results to be normalized based on the
amount protein, proportional to the number of cells in the sample, to determine if there is a
significant difference between conditions. This analysis is used to determine if initial infection of
lung epithelial cells with S. pneumoniae has an eﬀect on subsequent infection with adenovirus.
Not surprisingly, since the ratio is a function of luminescence, the constant variance assumption
was again questionable, and another natural logarithm transformation was required. There is
strong evidence to suggest there is a signiﬁcant mean diﬀerence between the natural log of the
ratio for 1 and 2 (p value 0.0044). There is also strong evidence to suggest there is a signiﬁcant
mean diﬀerence between the natural log of the ratio for 1 and 3 (p value <0.0001). Lastly, there
is strong evidence to suggest there is a signiﬁcant mean diﬀerence between the natural log of the
luminescence for 2 and 3 (p value <0.0001).
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Figure 3: Boxplots for ratio by condition. **Significant difference between condition 1 and 2, (p
value = 0.0044). *** Significant difference in the conditions of interest (3) compared to
condition 1 and 2, where both p values were <0.0001.
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Quantitative Polymerase Chain Reaction
Since Adenovirus has a DNA viral genome, DNA was isolated, and qPCR was used to
determine the amount of cell-associated viral genomes. Determining whether initial infection of
lung epithelial cells with Streptococcus pneumoniae has an eﬀect on the amount of viral genome
that is associated with the cells was determined in terms of relative quantification (RQ). Each
sample was measured in duplicate to ensure validity of the RQ values. Since the duplicate
measurements were identical, only one of them was used in the statistical analysis. Conditions 1,
2, and 3 are the focus of the results, so these were the only experimental conditions that were
included in the statistical analysis. However, the analysis of variance resulted in a p value of
0.11, meaning there is not suﬃcient evidence to suggest there are any signiﬁcant diﬀerences
between any of the three conditions.
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Figure 4: Boxplots for RQ by condition.
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IV. DISCUSSION
The results of the experiments suggest that cell-associated AdLacZ viral genome was not
affected by the presence of S. pneumoniae, but that the expression of the reporter gene in the
AdV genome was hindered by initial infection of the Calu-3 cells with Streptococcus
pneumoniae. The original hypothesis was that S. pneumoniae and AdV co-infections on
polarized airway epithelial cells (CaLu-3 cells) will lead to decreased AdV transduction. An
explanation for decreased AdV transduction is a decrease in CAREx8 receptors on the apical
surface of the CaLu-3 cells. Another explanation could be the destruction of the CAR receptor by
S. pneumoniae.
An explanation for decreased adenovirus transduction could be that initial infection of
cells with S. pneumoniae activates an innate immune response in epithelial cells that served as a
defense from the viral DNA expression. Lung epithelia produce surfactant proteins SP-A and SPD that have opsonizing properties (33). Lung epithelial cells also secrete anti-microbial peptides.
Beta-defensens are amphipathic antimicrobial peptides that form pores in microbial lipid bilayers
(33 page 47). It has been shown that pneumococcal infection activates Type 1 IFN expression
response in respiratory epithelial cells (27). Epithelial cells can also produce chemokines and
cytokines including IL-1β, IL-8, IL-6. Other studies have shown that bacterial pathogenassociated molecular patterns (PAMPs) within the phagolysosome can produce a response that
can mimic viral infection (28). Whether one or more of these pathways of the innate immune
recognition of S. pneumoniae is activated still requires further identification. However, these
responses may be shared between the S. pneumoniae and Adv.
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The results of these experiments produced a model system to investigate co-infection of
airway epithelia. The results also provide a greater understanding into how co-infections affect
the innate immune response.
Future Studies
Future studies should identify which pathways are activated and whether there is any
up/down regulation of the AdV receptor CAR on epithelial airway cells. Measurement of
cytokines IL-1β, IL-8, IL-6 production by Calu-3 cells would help understand the host cell innate
defense responses. Western blot to quantitate CAR protein levels should also be performed.
Immunostaining for localization of CAR, Junctional Proteins like Zo-1, S. pneumoniae, and
Adenovirus by confocal microscopy. This information could be utilized for prospective studies
of AdV as vector for gene therapy and further understanding of AdV and S. pneumoniae
pathogenesis on airway epithelia. A further analysis of the mechanism of this interplay is still to
be elucidated. These data show that pathogen-pathogen interactions can be important modulators
of lung infection.

.
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